医学临床研究
  2025年7月25日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (7): 1045-1047    DOI: 10.3969/j.issn.1671-7171.2021.07.024
  论著 本期目录 | 过刊浏览 | 高级检索 |
循环circRNA MICRA水平在AMI患者中的变化及临床意义
郑俊晨1, 周晓林2*
1.延安大学附属医院东关分院,陕西 延安 716000;
2.宝鸡西机医院,陕西 宝鸡 722400
Level and Value of circRNA MICRA in Patients with Acute Myocardial Infarction
ZHENG Jun-chen, ZHOU Xiao-lin
Yan'an University Affiliated Hospital,Yan'an Shaanxi 716000
全文: PDF (1209 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨AMI患者循环circRNA MICRA水平变化及其临床意义。【方法】选择2017年1月至2018年5月本院收治的73例AMI患者的临床资料(观察组),同时选择同期于本院健康体检的73例健康志愿者(对照组)。入组即刻抽取所有入选者外周血备用,检测循环circRNA MICRA水平,同时AMI患者出院后均随访6个月,记录主要不良心血管事件(MACE),比较两组受试者MICRA水平差异及MICRA水平与AMI预后的相关性。【结果】观察组循环MICRA水平为1.63±0.28,显著低于对照组的2.97±0.74,差异有统计学意义(t=14.470,P<0.01)。ROC评估MICRA作为AMI诊断标记物的效能显示,其曲线下面积(AUC)(95%CI)为0.81(0.73~0.90),最佳诊断界值为1.47。预后不良组患者循环MICRA为0.87±0.22,显著低于预后良好组患者2.19±0.85,差异有统计学意义(t=12.845,P<0.01)。【结论】循环circRNA MICRA在AMI患者中表达下调,同时与AMI患者预后密切相关,是潜在的诊断及评估AMI患者的生物学标记物。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
郑俊晨
周晓林
关键词 心肌梗死/遗传学急性病生物标记预后    
Abstract:【Objective】To analyze the level of circRNA MICRA in patients with acute myocardial infarction(AMI) and its clinical significance. 【Methods】A total of 73 patients with AMI who were diagnosed in the department of cardiology from January 2017 to May 2018 were enrolled as the AMI group and 73 healthy volunteers examined in the same time period in our hospital were included as healthy controls(HC) group. Venous blood was drawn from subjects immediately at admission to detect level of circRNA MICRA, and AMI patients were followed up 6 months after discharge and the major adverse cardiovascular events(MACE) in the group were recorded. MICRA levels were compared between the AMI and HC groups to explore the difference in level and the correlation between level of MICRA and AMI condition and prognosis. 【Results】Compared to the HC group, the level of MICRA in AMI group was significantly reduced [(1.63±0.28) vs(2.97±0.74), t=14.470, P<0.01];Receiver Operation Characterist Curve(ROC) evaluation of the effectiveness of MICRA as a diagnostic marker for AMI showed that the area under the curve(AUC)(95% CI) was 0.81(0.73-0.90) and the cutoff value was 1.47.Compared to patients with good prognosis, patients with poor prognosis had lower MICRA levels [(0.87±0.22) vs(2.19±0.85), t=12.845, P<0.01]. 【Conclusion】Level of MICRA was down-regulated in AMI patients and was closely related to AMI patient prognosis. It is a potential biomarker for the diagnosis and evaluation of AMI patients.
Key wordsMyocardial Infarction/GE    Acute Disease    Biomarkers    Prognosis
收稿日期: 2019-10-15     
中图分类号:  R542.22  
通讯作者: *E-mail:13892946539@163.com   
引用本文:   
郑俊晨, 周晓林. 循环circRNA MICRA水平在AMI患者中的变化及临床意义[J]. 医学临床研究, 2021, 38(7): 1045-1047.
ZHENG Jun-chen, ZHOU Xiao-lin. Level and Value of circRNA MICRA in Patients with Acute Myocardial Infarction. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 1045-1047.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.07.024     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I7/1045
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn